Treatments · the misinformation we still meet

Eight HRT myths, and the honest answer for each.

More than 20 years after the Women's Health Initiative press conference, the misinformation it set off is still keeping women off treatment that would have helped them. Here's what the evidence actually says, written without the medical defensiveness or the activist overcorrection.

Why this page exists

HRT is one of the most studied medications in modern medicine, and one of the most persistently misunderstood. A generation of women were taken off it in 2002 on the strength of a press conference, and a generation of doctors was trained in its shadow. The picture has shifted considerably since, but the public conversation hasn't fully caught up. This isn't a sales pitch for HRT, it's the honest answer to the eight things you'll most likely hear from a friend, a forum, or sometimes a doctor who hasn't updated since the early 2000s.

Myth 01
HRT causes breast cancer
It's a small, dose-and-duration-dependent increase, not the screaming headline of 2002.
The 2002 WHI headline number, 'a 26% increase in breast cancer risk', was the relative risk. The absolute risk it described was 8 extra cases per 10,000 women per year on combined HRT, smaller than the risk attributed to drinking two glasses of wine a night or being five units of BMI heavier. Estrogen-only HRT (for women without a uterus) didn't increase the risk at all and possibly lowered it. The current expert consensus: for most women starting HRT in their 40s and 50s for symptom relief, the breast-cancer signal is real but small, and the trade-off against quality of life, bone, cardiovascular and mood outcomes generally favours treatment. The honest sentence is 'small increase, mostly with the synthetic progestin, mostly after several years', not 'HRT causes cancer'.
Myth 02
The Women's Health Initiative proved HRT is dangerous
WHI tested one specific combination in mostly older women and found a much narrower problem than the press conference said.
The WHI study used conjugated equine estrogen plus medroxyprogesterone acetate (a synthetic progestin), in women whose average age was 63 and whose average distance from menopause was 12 years. That isn't most of the women asking about HRT today. When the same data is re-analysed by age at starting, the women who began HRT within ten years of menopause didn't show the cardiovascular harm the headline claimed, and several outcomes (mortality, hip fracture) actually favoured treatment. WHI is not a 'never start HRT' study. It's a 'don't start HRT for the first time at 65 to prevent heart disease' study, which is what the current guidelines actually say.
Myth 03
Body-identical HRT is just marketing
Body-identical (regulated estradiol and micronized progesterone) is a real, measurable thing. 'Bioidentical compounded' is the marketing term to be careful of.
Regulated body-identical HRT (transdermal estradiol, oral micronized progesterone) is chemically identical to the hormones the ovary makes, available on prescription, and dose-tested through manufacturing standards. Compounded 'bioidentical' hormones, mixed by a private pharmacy from a private clinic's prescription, are also chemically identical but are not dose-tested batch by batch, are not licensed, and are usually significantly more expensive. The two are often deliberately conflated in marketing. The honest position: ask for the regulated body-identical option first; the compounded version exists but the case for it over the licensed product is weak in most situations.
Myth 04
Natural is safer
'Natural' isn't a regulatory category. Plant-derived estrogens still carry estrogenic risk; herbs aren't tested the way drugs are.
Soy isoflavones, black cohosh, red clover and dong quai all act on estrogen pathways to varying degrees, with varying evidence behind them. Some have modest signals for hot flashes; most have small effects at best. None of them are 'risk-free because they're plants'. Black cohosh in particular has been linked to rare cases of liver injury. Compounded creams labelled 'natural progesterone' are still pharmacological doses of progesterone with the same effects as the prescription version. The framing that should sound the alarm is 'this is natural so it must be safe', that's not how pharmacology works in either direction.
Myth 05
You should stop HRT after five years
There's no fixed time limit. The trade-off should be reviewed periodically, not auto-stopped on a deadline.
The 'five years and you must stop' rule was extrapolated from the original WHI panic and never came from the actual evidence. Current guidelines (North American Menopause Society (NAMS) / Menopause Society, UK National Institute for Health and Care Excellence (NICE), BMS, IMS) all explicitly say there's no arbitrary upper time limit. The right approach is a periodic review (usually annually) of why you're on it, what's working, what's changed, and what the personal trade-off looks like. Some women come off after a few years because symptoms have settled; others stay on for decades because the symptom return is intolerable and the bone and cardiovascular benefits are real. Both can be the right answer.
Myth 06
If your symptoms aren't severe, you don't need HRT
Severity is one factor; the timing window, your bone and cardiovascular risk, and your quality of life are all part of the picture.
The 'wait until you can't function' framing misses two things. First, the timing window: starting HRT in early menopause (within ten years of the final period, or before age 60) appears to carry a more favourable risk-benefit profile than starting it later. Second, HRT isn't only about flushes; it has measurable effects on bone density, genitourinary syndrome of menopause (GSM), sleep architecture and, in some studies, cardiovascular risk markers. If your symptoms are real and affecting your life, even at a 4-out-of-10 not a 9-out-of-10, that's a legitimate reason to discuss treatment. Suffering more first is not a clinical requirement.
Myth 07
HRT just delays the inevitable; symptoms come back when you stop
Some symptoms can rebound on stopping; tapering helps. But you've also bought yourself the years on it, which counts.
Some women find vasomotor symptoms return when they come off HRT, particularly if they stop abruptly. A slow taper over several months reduces the rebound for most. But this 'you'll just have to do it eventually' framing assumes the years on HRT don't count, which they do. Better sleep, better mood, lower fracture risk, better sexual function and (for many) better cognition during your 50s and 60s aren't a postponement, they're the years themselves. If symptoms recur on stopping and they're bad enough to need treatment again, restarting is reasonable in most cases.
Myth 08
Vaginal estrogen is the same risk profile as systemic HRT
It isn't. Local vaginal estrogen is one of the safest treatments in menopause medicine.
Vaginal estrogen creams, rings and tablets deliver tiny doses locally, and systemic absorption is minimal. The breast-cancer warnings printed on the packet (a regulatory copy-paste from systemic HRT) significantly overstated the actual risk; current expert consensus is that local vaginal estrogen is appropriate for most women, including most breast-cancer survivors after a careful conversation with their oncologist. GSM, the cluster of vaginal and urinary symptoms that gets worse over time without treatment, is one of the most under-treated areas of menopause care precisely because of this misunderstanding. The good news, finally: in 2025, after years of advocacy led by the US nonprofit Let's Talk Menopause and the Menopause Advocacy Working Group, the FDA agreed to remove the boxed ("black box") warning from local vaginal estrogen products. Decades of evidence had not supported it. If a doctor or specialist or pharmacist still cites the old leaflet at you, that change is your evidence.

What changed. November 2025, finalised February 2026

The US FDA removed the "Black Box" warning from menopausal hormone therapy labels, the warning that came out of the 2002 WHI scare and has shaped two decades of doctor or specialist caution. The label changes were formally approved across six MHT products (Vivelle-Dot, Climara, Premarin, Prempro and others) in February 2026. The Canadian Menopause Society and others welcomed it as long overdue. Read the CMS statement · HHS / FDA fact sheet

Heads up: demand has jumped about 26% since the warning came off, and estrogen patches (Climara, Vivelle-Dot, generics) are still intermittently short across the US and parts of Canada into mid-2026. Reuters and NBC News are reporting that some manufacturers expect the supply gap could run another two to three years. If your pharmacy can't fill, ask your doctor about gel or spray as a like-for-like swap rather than coming off. We're tracking the policy side on rights and access.

Where to next

Back to the menu